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OBJECTIVES: Atherothrombosis is the leading cause of death
worldwide which creates a huge economic burden. The REACH
Registry is an international prospective registry with 67,888
patients from 44 countries, at risk of atherothrombotic events
due to coronary artery (CAD), cerebrovascular (CVD) and/or
peripheral arterial disease (PAD), or the presence of ≥3
atherothrombotic risk factors. METHODS: We examined med-
ication (MED) use and estimated annual MED costs (€) in 5594,
2516, and 618 patients from Germany (GE), Spain (SP) and 
the UK, respectively, using baseline data from REACH. Classes
of drugs examined included antiplatelet agents, oral anticoagu-
lants, NSAIDS, lipid lowering agents, antihypertension agents,
nitrates or other anti-angina agents, and peripheral arterial clau-
dication medications. Country-speciﬁc unit costs were obtained
for the 3–4 most commonly prescribed drugs in each MED cat-
egory, and a weighted average of MED-speciﬁc costs, by market
share, was applied to annualized utilization rates. RESULTS:
Within each country, average # MEDs increased with # diseased
vascular sites (GE:3.6/4.3/5.0;SP:3.4/3.8/4.1;UK:3.6/4.2/4.7, 
for 0/1/2–3 vascular sites, respectively). Patients with CAD 
only reported greater # MEDs (GE:4.7;SP:4.5;UK:4.4) than
patients with CVD only (GE:3.7;SP:3.0;UK:3.3) or PAD only
(GE:3.5;SP:2.5;UK:3.1). Greater than two thirds reported taking
at least 1 lipid lowering agent (GE:74%;SP:68%;UK:85%), 
and >85% reported taking at least 1 antihypertensive agent
(GE:94%;SP:86%;UK:88%). Average costs were higher for GE
compared to SP and UK due to higher unit costs for nearly all
MEDs. Lipid lowering and antihypertensive agents accounted for
>50% of MED costs (GE:70%;SP:54%;UK76%). Costs tended
to increase with # diseased vascular sites (GE:€770/€993/
€1164;SP:€492/€586/€710;UK:€546/€553/€668, for 0/1/2–3 vas-
cular sites, respectively). CONCLUSION: In this population of
patients with either stable vascular disease or multiple
atherothrombotic risk factors, use of multiple medications was
common. Medication use and associated costs tend to increase
with the number of diseased vascular sites, and contribute to the
economic burden of atherothrombosis.
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OBJECTIVES: A Markov model was developed to compare the
cost-utility of statins available via prescription (Rx) versus hypo-
thetical over the counter (OTC) status in the USA. METHODS:
Cost-utility of Rx statins and hypothetical OTC statins was
ascertained from a societal perspective in US dollars expended
per quality-adjusted life-years ($/QALYs) using a Markov model
over 10 years. The probability rates for coronary events and
coronary deaths were obtained from 8 randomized clinical trials,
and rate of adverse drug events were obtained from national pre-
scribing services. Baseline costs (including drugs, adverse events,
cardiovascular events, physician visits) and health outcomes
were discounted at 5% annually. Average acquisition and dis-
pensing costs for Rx statins were compared to the assumed
average lower dose costs for potential OTC statins in the United
States. RESULTS: Based on societal drug acquisition costs with
basic assumptions, OTC statins would be less expensive com-
pared to the Rx statins. OTC statins had a calculated cost-utility
of $1490/ QALY compared to $1914/ QALY for Rx statins.
Varying the discount rate simultaneously for cost and QALYs
from 0%–10% resulted in a $/QALY gained for Rx ranging from
$1951 to $1880 respectively, compared to the OTC range of
$1533 to $1450. CONCLUSIONS: Rx statins with baseline
assumptions had a higher percent LDL reduction and fewer coro-
nary events. Rx statins had higher cost per QALYs gained and
OTC statins were observed to be the optimal strategy choice.
More research is needed on the impact of OTC statins, includ-
ing appropriate assessment of lab monitoring, adverse event
monitoring and compliance and adherence measures to facilitate
a better understanding of the clinical and economic outcomes.
Availability of future lipid lowering drugs with varying acquisi-
tion costs and potency will require further analyses.
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OBJECTIVES: To evaluate the pharmacoeconomics of hawthorn
extract (crataegus), compared to any other therapy of congestive
heart failure (CHF), NYHA II, a prospective, 3-year, observa-
tional cohort study was conducted from 1999 to 2002. A cost-
utility-analysis was performed to compare the direct costs of the
treatment alternatives proportional to health related quality-of-
life (costs per quality-adjusted life year). METHODS: The open
observational study with matched-pairs evaluation included
general practitioners and internists. The crataegus cohort (CC)
comprised patients who received WS® 1442 for CHF (mono or
add-on). In the Standard cohort (SC), patients who reveived any
other treatment but crataegus were observed. Efﬁcacy and toler-
ability of the treatment alternatives were evaluated. Calculation
of the direct costs of the treatment comprised costs for diagnos-
tic and therapeutic measures, drugs and hospitalisations, cure and
rehabilitation measures. For measuring the patients’ quality-of-
life and calculating the gained quality-adjusted life years (QALY),
the EuroQoL-5D was applied. RESULTS: Data of 153 pairs (306
patients) were available for the statistical analysis. The pairs were
established based on age, gender and concomitant cardiac dis-
eases. Both efﬁcacy and tolerability of the crataegus therapy were
evaluated as signiﬁcant superior to standard therapy. Mean direct
costs per year amounted to €807.15 in cohort C and €798.09 in
cohort S. Gained quality-adjusted life years were 0.080 and 0.078
in the C- and the S-cohort, respectively. CONCLUSIONS: Direct
costs and gained QALY were similar in both cohorts. Both mono
and add-on applications of crataegus extract in the treatment of
congestive heart failure, NYHA II, represent a cost-effective alter-
native compared to standard medication. Crataegus treatment
was associated with a substitution of standard medication like
ACE-inhibitors and diuretics. Concerning the documented very
good tolerability of crataegus and the need of long-term treat-
ment of the considered indication, crataegus therapy provides an
additional beneﬁt for the affected patients.
